Hepatitis C therapy update

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Purpose of Review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. Recent Findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

Original languageEnglish (US)
Pages (from-to)188-192
Number of pages5
JournalCurrent Opinion in Gastroenterology
Volume28
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Hepatitis C
Genotype
Therapeutics
Interferons
Ribavirin
Antiviral Agents
Anemia
Clinical Trials
Pharmaceutical Preparations
Population

Keywords

  • boceprevir
  • direct-acting antivirals
  • hepatitis C virus
  • protease inhibitor
  • telaprevir

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hepatitis C therapy update. / Casey, Lisa C.; Lee, William M.

In: Current Opinion in Gastroenterology, Vol. 28, No. 3, 05.2012, p. 188-192.

Research output: Contribution to journalArticle

@article{9508f1af4a324ff3bf49a0b5ba789493,
title = "Hepatitis C therapy update",
abstract = "Purpose of Review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. Recent Findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.",
keywords = "boceprevir, direct-acting antivirals, hepatitis C virus, protease inhibitor, telaprevir",
author = "Casey, {Lisa C.} and Lee, {William M.}",
year = "2012",
month = "5",
doi = "10.1097/MOG.0b013e3283528e1e",
language = "English (US)",
volume = "28",
pages = "188--192",
journal = "Current Opinion in Gastroenterology",
issn = "0267-1379",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Hepatitis C therapy update

AU - Casey, Lisa C.

AU - Lee, William M.

PY - 2012/5

Y1 - 2012/5

N2 - Purpose of Review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. Recent Findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

AB - Purpose of Review: We review here the recent literature regarding hepatitis C treatment through January 2012. We discuss newly approved therapies and their clinical trial data and discuss what can be expected in this rapidly changing field. Recent Findings: Two new directly acting antiviral agents were approved in 2011 for use in hepatitis C treatment, bringing shortened treatment durations, and increased treatment success to some patients with genotype 1 hepatitis C. Additional drugs using different viral targets are in development to further improve response rates, tolerance, and increase access to therapy. Summary: Telaprevir and boceprevir were approved in 2011 for use against genotype 1 hepatitis C, in combination with pegylated interferon and ribavirin. In most populations of genotype 1 patients, response rates are much improved but increased treatment related anemia has been seen. Additional options for therapy, including interferon-free regimens, are still needed and are under development.

KW - boceprevir

KW - direct-acting antivirals

KW - hepatitis C virus

KW - protease inhibitor

KW - telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84859921024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859921024&partnerID=8YFLogxK

U2 - 10.1097/MOG.0b013e3283528e1e

DO - 10.1097/MOG.0b013e3283528e1e

M3 - Article

VL - 28

SP - 188

EP - 192

JO - Current Opinion in Gastroenterology

JF - Current Opinion in Gastroenterology

SN - 0267-1379

IS - 3

ER -